Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018.

2.

Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary.

Paine MF, Shen DD, McCune JS.

Drug Metab Dispos. 2018 Jul;46(7):1041-1045. doi: 10.1124/dmd.117.079962. Epub 2018 May 7.

PMID:
29735755
3.

Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach.

Johnson EJ, González-Peréz V, Tian DD, Lin YS, Unadkat JD, Rettie AE, Shen DD, McCune JS, Paine MF.

Drug Metab Dispos. 2018 Jul;46(7):1046-1052. doi: 10.1124/dmd.118.081273. Epub 2018 May 7.

PMID:
29735752
4.

Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.

McCune JS, Storer B, Thomas S, McKiernan J, Gupta R, Sandmaier BM.

Biol Blood Marrow Transplant. 2018 Apr 12. pii: S1083-8791(18)30187-3. doi: 10.1016/j.bbmt.2018.04.006. [Epub ahead of print]

PMID:
29656138
5.

Rapid Advances in Immunotherapy to Treat Cancer.

McCune JS.

Clin Pharmacol Ther. 2018 Apr;103(4):540-544. doi: 10.1002/cpt.985.

PMID:
29527663
6.

Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation.

Tian DD, Kellogg JJ, Okut N, Oberlies NH, Cech NB, Shen DD, McCune JS, Paine MF.

Drug Metab Dispos. 2018 May;46(5):552-560. doi: 10.1124/dmd.117.079491. Epub 2018 Feb 21.

PMID:
29467215
7.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

PMID:
28880971
8.

Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Lin YS, Kerr SJ, Randolph T, Shireman LM, Senn T, McCune JS.

Metabolomics. 2016 Oct;12(10). pii: 161. doi: 10.1007/s11306-016-1106-6. Epub 2016 Sep 15.

9.

Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.

Farr N, Wang YN, D'Andrea S, Starr F, Partanen A, Gravelle KM, McCune JS, Risler LJ, Whang SG, Chang A, Hingorani SR, Lee D, Hwang JH.

Int J Hyperthermia. 2018 May;34(3):284-291. doi: 10.1080/02656736.2017.1336675. Epub 2017 Jul 17.

PMID:
28715967
10.
11.

Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (Camellia sinensis) as a Case Study.

Kellogg JJ, Graf TN, Paine MF, McCune JS, Kvalheim OM, Oberlies NH, Cech NB.

J Nat Prod. 2017 May 26;80(5):1457-1466. doi: 10.1021/acs.jnatprod.6b01156. Epub 2017 Apr 28.

12.

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Review.

PMID:
28182269
13.

Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.

McDonald GB, Evans AT, McCune JS, Schoch G, Ostrow JD, Gooley TA.

Lancet Haematol. 2016 Nov;3(11):e516-e525. doi: 10.1016/S2352-3026(16)30149-1.

PMID:
27968820
14.

Immunotherapy to Treat Cancer.

McCune JS.

Clin Pharmacol Ther. 2016 Sep;100(3):198-203. doi: 10.1002/cpt.404.

PMID:
27513619
15.

Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29. Review.

16.

Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.

Navarro SL, Randolph TW, Shireman LM, Raftery D, McCune JS.

J Proteome Res. 2016 Aug 5;15(8):2802-11. doi: 10.1021/acs.jproteome.6b00370. Epub 2016 Jul 20.

17.

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, McCune JS, Bensinger WI, Maloney DG, Press OW, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1582-1587. doi: 10.1016/j.bbmt.2016.06.007. Epub 2016 Jun 14.

18.

Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.

Floeter AE, McCune JS.

J Oncol Pharm Pract. 2017 Jul;23(5):344-349. doi: 10.1177/1078155216651128. Epub 2016 May 20.

PMID:
27208016
19.

The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.

McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, Greenlee S, Valderrama A, Sullivan SD, Ramsey SD.

Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.

20.

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.

Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ.

Blood. 2016 Mar 17;127(11):1502-8. doi: 10.1182/blood-2015-10-672071. Epub 2016 Jan 13.

21.

Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

McCune JS, Bemer MJ, Long-Boyle J.

Clin Pharmacokinet. 2016 May;55(5):551-93. doi: 10.1007/s40262-015-0340-9. Review.

22.

Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

McCune JS, Bemer MJ.

Clin Pharmacokinet. 2016 May;55(5):525-50. doi: 10.1007/s40262-015-0339-2. Review.

23.

Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.

Li T, Wang YN, Khokhlova TD, D'Andrea S, Starr F, Chen H, McCune JS, Risler LJ, Mashadi-Hossein A, Hingorani SR, Chang A, Hwang JH.

Cancer Res. 2015 Sep 15;75(18):3738-46. doi: 10.1158/0008-5472.CAN-15-0296. Epub 2015 Jul 27. Erratum in: Cancer Res. 2017 May 15;77(10 ):2771.

24.

Developing and Using Therapeutics for Emerging Infections.

McCune JS, Reynolds KS.

Clin Pharmacol Ther. 2015 Oct;98(4):346-51. doi: 10.1002/cpt.183.

PMID:
26179402
25.

Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

McCune JS, Mager DE, Bemer MJ, Sandmaier BM, Storer BE, Heimfeld S.

Cancer Chemother Pharmacol. 2015 Jul;76(1):85-96. doi: 10.1007/s00280-015-2768-x. Epub 2015 May 17.

26.

Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.

Overby CL, Devine EB, Abernethy N, McCune JS, Tarczy-Hornoch P.

J Biomed Inform. 2015 Jun;55:249-59. doi: 10.1016/j.jbi.2015.04.011. Epub 2015 May 7.

27.

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

McCune JS, Vicini P, Salinger DH, O'Donnell PV, Sandmaier BM, Anasetti C, Mager DE.

Cancer Chemother Pharmacol. 2015 Jan;75(1):67-75. doi: 10.1007/s00280-014-2618-2. Epub 2014 Nov 6.

28.

Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.

McCune JS, Jacobson P, Wiseman A, Militano O.

Bone Marrow Transplant. 2015 Feb;50(2):165-72. doi: 10.1038/bmt.2014.235. Epub 2014 Oct 27. Review.

29.

Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.

Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G.

Pediatr Hematol Oncol. 2014 Nov;31(8):731-42. doi: 10.3109/08880018.2014.927945. Epub 2014 Jul 9.

PMID:
25007236
30.

Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Bemer MJ, Risler LJ, Phillips BR, Wang J, Storer BE, Sandmaier BM, Duan H, Raccor BS, Boeckh MJ, McCune JS.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1544-52. doi: 10.1016/j.bbmt.2014.05.032. Epub 2014 Jun 9.

31.

Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.

Diestelhorst C, Boos J, McCune JS, Hempel G.

Eur J Clin Pharmacol. 2014 Jul;70(7):839-47. doi: 10.1007/s00228-014-1692-z. Epub 2014 May 9.

PMID:
24810613
32.

Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.

Li H, Mager DE, Sandmaier BM, Storer BE, Boeckh MJ, Bemer MJ, Phillips BR, Risler LJ, McCune JS.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1121-9. doi: 10.1016/j.bbmt.2014.03.032. Epub 2014 Apr 13.

33.

Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH.

Clin Cancer Res. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11.

34.

Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.

Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G.

Cancer Chemother Pharmacol. 2013 Nov;72(5):991-1000. doi: 10.1007/s00280-013-2275-x. Epub 2013 Sep 6.

PMID:
24061863
35.

A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.

Bemer MJ, Sorror M, Sandmaier BM, O'Donnell PV, McCune JS.

Cancer Chemother Pharmacol. 2013 Sep;72(3):607-18. doi: 10.1007/s00280-013-2232-8. Epub 2013 Aug 2.

36.

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.

Jaklič A, Collins CJ, Mrhar A, Sorror ML, Sandmaier BM, Bemer MJ, Locatelli I, McCune JS.

Int J Clin Pharmacol Ther. 2013 Sep;51(9):711-7. doi: 10.5414/CP201884.

37.

Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.

McDermott CL, Sandmaier BM, Storer B, Li H, Mager DE, Boeckh MJ, Bemer MJ, Knutson J, McCune JS.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1159-66. doi: 10.1016/j.bbmt.2013.04.026. Epub 2013 May 6.

38.

Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Rezvani AR, McCune JS, Storer BE, Batchelder A, Kida A, Deeg HJ, McDonald GB.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1033-9. doi: 10.1016/j.bbmt.2013.04.005. Epub 2013 Apr 10.

39.

Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.

McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JS.

J Clin Pharmacol. 2013 Mar;53(3):264-75. doi: 10.1177/0091270012447196. Epub 2013 Jan 24.

40.

Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.

Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS.

J Clin Pharmacol. 2013 Apr;53(4):393-402. doi: 10.1002/jcph.14. Epub 2013 Feb 4.

41.

Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia.

Chow EJ, Pihoker C, Friedman DL, Lee SJ, McCune JS, Wharton C, Roth CL, Baker KS.

Pediatr Blood Cancer. 2013 Apr;60(4):621-6. doi: 10.1002/pbc.24364. Epub 2012 Oct 5.

42.

Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.

McCune JS, Sullivan SD, Blough DK, Clarke L, McDermott C, Malin J, Ramsey S.

Pharmacotherapy. 2012 Jan;32(1):7-19. doi: 10.1002/PHAR.1008.

PMID:
22392824
43.

A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients.

Li H, Mager DE, Bemer MJ, Salinger DH, Vicini P, Sandmaier BM, Nash R, McCune JS.

J Clin Pharmacol. 2012 Nov;52(11):1654-64. doi: 10.1177/0091270011429567. Epub 2011 Dec 14.

44.

Patterns of blood product use among patients with myelodysplastic syndrome.

Ramsey SD, McCune JS, Blough DK, McDermott CL, Beck SJ, López JA, Deeg HJ.

Vox Sang. 2012 May;102(4):331-7. doi: 10.1111/j.1423-0410.2011.01568.x. Epub 2011 Nov 24.

45.

A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions.

McDermott CL, Hsieh AA, Sweet ES, Tippens KM, McCune JS.

J Altern Complement Med. 2011 Nov;17(11):1043-9. doi: 10.1089/acm.2010.0471.

46.

Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.

Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA.

Drug Metab Dispos. 2012 Jan;40(1):54-63. doi: 10.1124/dmd.111.039347. Epub 2011 Oct 5.

47.

A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients.

McCune JS, Woodahl EL, Furlong T, Storer B, Wang J, Heimfeld S, Deeg HJ, O'Donnell PV.

Cancer Chemother Pharmacol. 2012 Jan;69(1):263-72. doi: 10.1007/s00280-011-1736-3. Epub 2011 Sep 11.

48.

Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.

Yeh RF, Pawlikowski MA, Blough DK, McDonald GB, O'Donnell PV, Rezvani A, Deeg HJ, McCune JS.

Biol Blood Marrow Transplant. 2012 Feb;18(2):265-72. doi: 10.1016/j.bbmt.2011.06.013. Epub 2011 Jul 4.

49.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation.

Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R.

Bone Marrow Transplant. 2012 Apr;47(4):581-8. doi: 10.1038/bmt.2011.104. Epub 2011 May 9.

50.

Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation.

Bubalo JS, Cherala G, McCune JS, Munar MY, Tse S, Maziarz R.

J Clin Pharmacol. 2012 Apr;52(4):586-94. doi: 10.1177/0091270011398243. Epub 2011 Mar 17.

PMID:
21415280

Supplemental Content

Loading ...
Support Center